Levonorgestrel: 5 agencies, 2013–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PHARMAC (New Zealand) has been easier on levonorgestrel than on its own caseload: it refused 0 of 5 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
The file has been open for more than a decade: 13 years separate the first record, 6 Feb 2013 at HAS (France), from the most recent, 4 Feb 2026 at HAS (France).
HAS (France) changed its position: recommended on 6 Nov 2013, not recommended by 4 Feb 2026.
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
5 distinct indication wordings are recorded for levonorgestrel by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 25 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess levonorgestrel, on 6 Feb 2013; PBAC (Australia) did not open a file until 2019 — a wide spread of 6.4 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
4 of the 5 agencies here assessed levonorgestrel more than once, HAS (France) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed levonorgestrel.
The full ledger for levonorgestrel reads 19 recommended, 3 not assessed, 2 other and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 11 Jan 2022 | Contraception. Treatment of heavy menstrual bleeding | outside AWMSG criteria | source |
| HAS (France) | 21 Apr 2021 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2019 | Contraception | The PBAC recommended the listing of a new form of levonorgestrel (Kyleena®) as a Restricte… | source |
| SMC (Scotland) | 12 Feb 2018 | Contraception for up to 5 years. | accepted | source |
| PHARMAC (New Zealand) | 8 Feb 2018 | Contraception - long acting reversible contraception | PTAC advice: High · decision reached | source |
20 further decisions for levonorgestrel, across 4 agencies, are not shown here. They include the most recent record on file, 4 Feb 2026 from HAS (France); its outcome is in the subscriber dataset. They link to 17 further source documents.
Related molecules
- desogestrel — same ATC class G03A — Sex hormones and modulators
- desogestrel / ethinylestradiol — same ATC class G03A — Sex hormones and modulators
- etonogestrel — same ATC class G03A — Sex hormones and modulators
- medroxyprogesterone — same ATC class G03A — Sex hormones and modulators
- drospirenone — same ATC class G03A — Sex hormones and modulators
- vutrisiran — also decided by HAS in 2026Q1
Coverage: 25 decisions for levonorgestrel from 5 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class G03A — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.